1. Hot Off the Press: Changes in the Landscape of Multiple Myeloma

2. Program Goals

3. Outline

4. Diagnostic Criteria Multiple Myeloma Requiring Therapy

6. PFS and OS According to the R-ISS

7. Validation of the R-ISS

8. Selecting Therapy

9. Newly Diagnosed Multiple Myeloma Primary Induction for SCT Candidates

10. IFM 2013-04 VTD vs CyBorD in Newly Diagnosed MM

11. SWOG S0777 VRd vs Rd

12. Induction Therapy Conclusions

13. ASCT

14. STaMINA Trial BMT CTN 0702

15. Patients Ineligible for ASCT

16. FIRST Trial Continuous Rd vs Rd-18 vs MPT

17. Modified Lenalidomide, Bortezomib, and Dexamethasone

18. Consolidation and Maintenance

19. Lenalidomide Maintenance After ASCT A Meta-Analysis

20. Relapsed/Refractory MM

21. Agents Approved for R/R MM in 2015

22. ASPIRE KRd vs Rd

23. TOURMALINE-MM1 Ixazomib + Len/Dex vs Placebo + Len/Dex

24. ENDEAVOR Kd vs Vd

25. ELOQUENT-2 Elotuzumab + Len/Dex vs Len/Dex

26. Two Large Randomized Studies of Daratumumab Reported in 2016

27. CASTOR Study Daratumumab + Bor/Dex vs Bor/Dex

28. POLLUX Study Daratumumab + Len/Dex vs Len/Dex

29. Case

30. Considerations for Case

31. Select Emerging Agents in MM

32. Key Takeaways

33. Abbreviations

34. Abbreviations (cont)

35. Abbreviations (cont)

36. Abbreviations (cont)